Acute treatment of migraine with or without aura; Sumatriptan injection: Acute treatment of cluster headache episodes

Sumatriptan is indicated only in patient populations with a clear diagnosis of migraine or cluster headache Cardiac events (coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular

tachycardia/fibrillation, cardiac arrest and death) have been reported with 5-HT1 agonist administration. Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension. Vasospasm-related reactions have been reported other than coronary artery vasospasm. Peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea have occurred.

Intravenous administration; use in patients with ischemic heart disease or Prinzmetal angina, patients with signs or symptoms of ischemic heart disease, uncontrolled HTN; use with ergotamine derivatives (within 24 hours of); use with in 24 hours of another 5-HT1 agonist; concurrent administration or within 2 weeks of discontinuing an MAOI; hypersensitivity to any component; management of hemiplegic or basilar migraine

>10% : Central nervous system: Dizziness Endocrine & metabolic: Hot flashes Local: Injection site reaction Neuromuscular & skeletal: Paresthesia 1% to 10% : Cardiovascular: Tightness in

chest Central nervous system: Drowsiness, headache Dermatologic: Burning sensation Gastrointestinal: Abdominal discomfort, mouth discomfort. Neuromuscular & skeletal: Myalgia, numbness, weakness, neck pain, jaw discomfort Miscellaneous: Diaphoresis
<1% : Rashes, polydipsia, dehydration, dysmenorrhea, dysuria, renal calculus, dyspnea, thirst, hiccups

Increased toxicity: Ergot-containing drugs, MAOIs, SSRIs can lead to symptoms of hyper-reflexia, weakness, and incoordination

Take at first sign of migraine attack. This drug is to be used to reduce your migraine, not to prevent or reduce number of attacks. Oral: If headache returns or is not fully resolved after first dose, the dose may be

repeated after 2 hours. Do not exceed 300 mg in 24 hours. S.C.: If headache returns or is not fully resolved after first dose, the dose may be repeated after 1 hour.Do not exceed two injections in 24 hours. Do not take within 24 hours of any other migraine medication without first consulting prescriber. You may experience some dizziness (use caution); hot flashes (cool room may help); nausea or vomiting (frequent small meals, frequent mouth care, sucking lozenges, or chewing gum may help); pain at injection site (lasts about 1 hour, will resolve); or excess sweating (will resolve). Report chest tightness or pain; excessive drowsiness; acute abdominal pain; skin rash or burning sensation; muscle weakness, soreness, or numbness; or respiratory difficulty. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Consult prescriber if breast-feeding.